ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Epidemiology and characteristics of cases with monkeypox virus clade I in the WHO European Region, 2024 to 2025.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDA public health emergency of international concern (PHEIC) was declared in August 2024 following a sharp increase in mpox cases linked to the emergence of monkeypox virus (MPXV) clade Ib.AIMWe aimed to characterise imported and locally acquired mpox clade I cases reported in the WHO European Region (WHO/Europe) since August 2024 and assess transmission patterns and response measures.METHODSWe collected data on MPXV clade I infections reported by countries in WHO/Europe through the International Health Regulations. We contacted reporting countries to collect age, sex, travel history, most likely route of transmission, clinical course, contacts and type of exposure, and implemented control and prevention measures.RESULTSBetween 14 August 2024 and 23 November 2025, 82 cases of MPXV clade I infection were reported; 45 were imported and 37 were infected in reporting countries. Seventy-nine were typed as clade Ib and two as clade Ia. Most imported cases reported heterosexual (n = 26) or close physical contact (n = 5) as possible exposure. Secondary transmission occurred in six households. One healthcare worker was infected. Since October 2025, further 17 autochthonous male cases were most likely infected through sex with other men.CONCLUSIONImported cases of MPXV clade I infection were associated with limited household transmission. The increase in autochthonous infections among men with recent sexual contact with other men suggests undetected spread in Europe, that may become sustained. Continued surveillance, case and contact investigation are needed to understand MPXV clade I epidemiology and drivers of MPXV clade I transmission in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.